A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease

Peer Review reports

Original Submission
11 May 2022	Submitted	Original manuscript
Resubmission - Version 2
	Submitted	Manuscript version 2
11 Jul 2022	Reviewed	Reviewer Report
12 Jul 2022	Reviewed	Reviewer Report
11 Aug 2022	Author responded	Author comments - Deirdre Mladsi
Resubmission - Version 3
11 Aug 2022	Submitted	Manuscript version 3
26 Aug 2022	Reviewed	Reviewer Report
Resubmission - Version 4
	Submitted	Manuscript version 4
Publishing
12 Sep 2022	Editorially accepted
18 Oct 2022	Article published	10.1186/s12882-022-02956-8

Back to article page